Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ATTD 2022: Mic Drop Moment As Medtronic Presents 780G Data Proving Closed Loop Ability

Executive Summary

Results of the ADAPT study presented at the Advanced Technologies & Treatments for Diabetes conference in Barcelona support Medtronic’s hope that the 780g insulin pump will help to turn around its diabetes business or make it an attractive acquisition for another company.

You may also be interested in...



Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G

Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.

Minute Insight: Real-World Data Supports Medtronic’s 780G Insulin Pump

Postmarket data from Europe and Chile, announced at the American Diabetes Association conference, offer more support for Medtronic’s faith in its MiniMed 780G system with the Guardian 4 sensor.

Medtronic Starts Planned Portfolio Simplification With DaVita Renal Care Spin Off

The new independent kidney-care company will be equally co-owned by both companies. It will include all of Medtronic’s renal care solutions business, including renal access, acute therapies, and chronic therapies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel